Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Merck KGaA. (3/17/14). "Press Release: Merck Serono Appoints Meeta Gulyani to the Pharmaceutical Executive Committee as the Head of Strategy and Global Franchises". Darmstadt.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Roche (Group)
Products Product pharmaceutical
  Product 2 biopharmaceutical
Persons Person Gulyani, Meeta (Merck (DE) 201403– Head of Strategy + Global Franchises at Merck Serono before Roche + Sanofi)
  Person 2 Garijo, Belén (Merck (DE) 201310– CEO of Merck Serono before COO sinc 2011 before Sanofi)
     


Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Meeta Gulyani to the position of Head of Strategy and Global Franchises as of May 7, 2014. Mrs Gulyani will be based in Boston (United States) and will report to Belén Garijo, President and Chief Executive Officer of Merck Serono.

"I am very pleased to have Meeta on board as we are moving into a new phase of Merck Serono's transformation, focused on growth, and seek to maximize the value of our current product portfolio and build our future product offering", said Belén Garijo, President and Chief Executive Chief Executive Officer of Merck Serono. "Meeta is an accomplished executive with a leadership track record across strategic and operational roles in both mature and emerging markets and will bring the necessary expertise and global perspective required for this important role."

Mrs Gulyani will be leading Merck Serono's Global Franchises (Multiple Sclerosis & Immunology, Oncology, Fertility, General Medicine & Endocrinology, and Medical Devices), with a strong focus on defining integrated strategies for the different disease areas, ensuring rigorous allocation of resources in line with the strategy, as well supporting drive Merck Serono's operating performance through marketing excellence. With Meeta Gulyani's appointment, and further to the promotion of Elcin Ergun on January 1, 2014 as Head of Commercial, Merck Serono's Pharmaceutical Executive Committee is now complete.

Merck Serono has been strengthening its global management to compete with innovative drugs in mature markets such as Europe and North America as well as respond to rising medical needs in emerging markets, which already accounted for almost one-third of the division's € 5.96 billion sales in 2013.

Meeta Gulyani joins Merck Serono from Roche where she was most recently General Manager for South Asia, covering India, Sri Lanka, Bangladesh and Nepal, and previously Vice President of Global Portfolio Management. Prior to joining Roche in 2010, Mrs Gulyani spent eight years at Sanofi. She holds an MBA from the Asian Institute of Management, Philippines, accompanied by an exchange program at Wharton, University of Pennsylvania, USA, and a BA in Economics from the Shri Ram College of Commerce from the Delhi University, India.


About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit www.merckserono.com.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top